-
公开(公告)号：EP2475254A1
公开(公告)日：2012-07-18
申请号：EP10816134.0
申请日：2010-09-10
发明人： QIU, Yao-ling , WANG, Ce , YING, Lu , PENG, Xiaowen , OR, Yat, Sun
CPC分类号： A61K31/40 , C07D207/28 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/08
摘要： The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
摘要翻译： 本发明公开了抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的化合物或其药学上可接受的盐，酯或前药。 因此，本发明化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。 本发明进一步涉及包含前述化合物的药物组合物，用于给予患有HCV感染的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。 本发明涉及本文上述代表的新型抗病毒化合物，包含此类化合物的药物组合物以及用所述化合物治疗或预防需要这种治疗的受试者中的病毒（特别是HCV）感染的方法。
-
公开(公告)号：EP2528436A1
公开(公告)日：2012-12-05
申请号：EP11735350.8
申请日：2011-01-25
发明人： QIU, Yao-Ling , WANG, Ce , PENG, Xiaowen , YING, Lu , CAO, Hui , OR, Yat, Sun
IPC分类号： A01N43/00
CPC分类号： C07D498/18 , C07D519/00 , C07F9/6561
摘要： The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W (I) which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：EP2475256A1
公开(公告)日：2012-07-18
申请号：EP10816111.8
申请日：2010-09-10
发明人： OR, Yat, Sun , PENG, Xiaowen , WANG, Ce , YING, Lu , QIU, Yao-Ling
CPC分类号： C07D401/14 , A61K38/21 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07F9/65583 , C12N2770/24211
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
摘要翻译： 本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。 因此，本发明化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。 本发明进一步涉及包含前述化合物的药物组合物，用于给予患有HCV感染的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。 本发明涉及本文上述代表的新型抗病毒化合物，包含此类化合物的药物组合物以及用所述化合物治疗或预防需要这种治疗的受试者中的病毒（特别是HCV）感染的方法。
-
公开(公告)号：EP2393359A1
公开(公告)日：2011-12-14
申请号：EP10739272.2
申请日：2010-02-09
发明人： QIU, Yao-Ling , WANG, Ce , YING, Lu , PENG, Xiaowen , OR, Yat, Sun
IPC分类号： A01N43/50
CPC分类号： C07D403/14 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/08
摘要： The present invention discloses linked dibenzimidazole derivatives, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明公开了抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的连接的二苯并咪唑衍生物或其药学可接受的盐，酯或前药。 因此，本发明化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。 本发明进一步涉及包含前述化合物的药物组合物，用于给予患有HCV感染的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：EP2400846B1
公开(公告)日：2016-10-05
申请号：EP10746967.8
申请日：2010-03-01
发明人： QIU, Yao-ling , WANG, Ce , PENG, Xiaowen , YING, Lu , OR, Yat, Sun
IPC分类号： A01N43/52 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , A61K31/4184 , A61P31/12
CPC分类号： C07D405/14 , C07D401/14 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14
-
公开(公告)号：EP2768825A2
公开(公告)日：2014-08-27
申请号：EP12842330.8
申请日：2012-10-17
发明人： TANG, Datong , XU, Guoyou , PENG, Xiaowen , YING, Lu , WANG, Ce , CAO, Hui , LONG, Jiang , KIM, In, Jong , WANG, Guoqiang , QIU, Yao-ling , OR, Yat, Sun
IPC分类号： C07D403/14
CPC分类号： C07D403/14
摘要： The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a):
-
公开(公告)号：EP2512480A1
公开(公告)日：2012-10-24
申请号：EP10841521.7
申请日：2010-12-14
发明人： QIU, Yao-Ling , WANG, Ce , PENG, Xiaowen , CAO, Hui , YING, Lu , OR, Yat Sun
IPC分类号： A61K31/50
CPC分类号： C07D401/14 , A61K38/00 , C07D403/14 , C07D413/14
摘要： The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: (Formula (I)) which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译： 本发明公开了抑制含RNA病毒，特别是丙型肝炎病毒（HCV）的式（I）化合物或其药学上可接受的盐，酯或前药：（式（I））。 因此，本发明化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。 本发明进一步涉及包含前述化合物的药物组合物，用于给予患有HCV感染的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
-
公开(公告)号：EP2400846A1
公开(公告)日：2012-01-04
申请号：EP10746967.8
申请日：2010-03-01
发明人： QIU, Yao-ling , WANG, Ce , PENG, Xiaowen , YING, Lu , OR, Yat, Sun
IPC分类号： A01N43/52
CPC分类号： C07D405/14 , C07D401/14 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.02 秒)
